Post conference Expert Opinion

- Voice of Healthcare 4th International Conference 21th - 22nd February 2019 Pragati Maidan, New Delhi


- Dr. Naveen Nishchal, Chairman, Voice of Healthcare

I would like to take this opportunity to thank you all for the cooperation that I received from all quarters – right from the conceptualization, agenda spread out, speakers selection and confirmation, site preparation, hospitality and arrangement of the complete conference. It has been an excellent organized Conference as evident from the inputs that I am getting from the industry stalwarts.

Much has been debated in various sessions and it came out clear that the present scenario of healthcare is in India is not an easy one but it is heading towards a right direction. The Conference has set a platform to continue engaging in the matter with your valueable inputs, insights and knowledge.

This Post Conference Expert Opinion is a compilation of outlook and views of our distinguished speakers. Loaded with this, we appeal the policy makers to include the observation and suggestions in future roadmap.

Once again thank you for taking time out of your busy schedule to partake in the Conference.

- Mr. Afzal Kamal, Gen. Secretary, Voice of Healthcare

We hope you are equally elated with staging of an excellent Conference. By all accounts it was very well done with a very good and diverse set of speakers and high-level array of participants. The level and diversity of discussion were outstanding. We had just the right mix of subjects, people and time. The rich and frank discussions on several important issues helped us all to understand each other’s perspective. 

With this Post Conference Expert Opinion, I appeal to the government to provide an inclusive platform for all policy formation related to healthcare.

- Gaurav Malhotra, Managing Director Medicover Healthcare & VOH Conference Co- Chairman

I want to express my gratitude to all the speakers to honour our invitation and congratulate for the high level of organization and the professionalism which made it possible to gather so many different experts and develop all the activities with success. The conference was rich in content and valuable in creating better understanding of the issues that were discussed. I am grateful that I was asked to co-chair the conference.

Now it is up to the government and policy making authorities to utilise this Post Conference Expert Opinion in an effective manner and give new dimension to the healthcare industry of India.

- Dr. Hsu I Lin, Director International Medical Center, National Cheng Kung University Hospital, Taiwan, International Partner VOH Conference 2019

I sincerely congratulate you on the success of the Conference, which was well-organized, well-balanced, and had a very topical agenda. The speakers were all highly respected professionals, and the debate was dynamic. I believe that this opinion is shared by most of the participants.

Every panel I attended was engaging and insightful. In addition, the logistics were smooth and you have a wonderful team of people- all friendly and helpful. Thank you for the invitation to attend as International Parter, this was a delightful experience I wish you and your team further achievements, and hope for continued cooperation.

- Thomas Schlitt, Managing Director, Messe Düsseldorf India, Organiser-Medical Fair India

I wish to congratulate you on the beautiful success of the Conference. It was a splendid event, both in terms of intellectual quality and social gratification. The organization was smooth and efficient throughout. You can be proud of your achievement and of your staff’s contribution.

My congratulations once again on pulling off such a huge project so brilliantly

Agenda Day 1

9.30 am to 10.00 am -Registration

10.00 am to 11.30 am – MFI & VOH Inaugural session


VOH Journey – Depth and Breadth of it.

Welcome address by General Secretary

Mr. Afzal Kamal

VOH Update by Chairman, VOH

Dr. Naveen Nishchal

Address by Conference – Co Chairman – VOH

Mr. Gaurav Malhotra

Address by Guest of Honour

Professor – Chung Yi, Li -Professor – Department of Public Health – NCKU

Shri. Atul Kumar Nasa – Head of Office “Controlling & Licensing Authority,” Deputy Drug Controller – Drug Control Department Delhi

Message from Chief Guest

Shri Ashwini Choubey – Honorable Minister of State – MOHFW.GOI

Launch Of Medgate Coffee Table Book, MEDDO APP, VOH Academy

Shri Ashwini Choubey – Honorable Minister of State – MOHFW. GOI

Felicitation of dignitaries by Associate Director – VOH

Ms. Pinky Chahar

11.30 am – 11.45am: Key note on “Advantages of Taiwanese Medical System” – Dr. Hsu l Lin – Director – International Medical Center – National Cheng Kung University Hospital, Taiwan

11:45 am – 12:00 – Key note on “Nationwide Population Science – Research outcome from the Taiwan National Health Insurance Research Database” – Prof. Chung Yi, Li Department of Public Health – National Cheng Kung University, Taiwan.

12.00 – 12.10 pm : Knowledge session “Infection Prevention and The New Medical Devices Rules 2017- An Overview” by Sumit Marwah – CEO & Director, Dispoline Pvt. Ltd.

 12.10pm – 12:45 pm Panel Discussion – Healthcare Quality : Where are we heading to?

After affordability, quality is another big challenge for the Indian Healthcare Industry. We have been talking extensively about accreditation but where we are heading in the field of quality healthcare?

Moderator – Dr. B K Rana – Founder CEO – QAI
Panelist :
Sashi Rekha – Director – NABCB
Dr. Harish Nadkarni – CEO – NABH
Dr. Neeraj Jain – Secretary – The Association of Practicing Pathologist
Dr. Sanjeev Sood – NABH Assessor – Advisor AHPI, Delhi
Rajiv Nath- Forum Co-ordinator AiMed
Dr. Barnali Das – Consultant – Laboratory Medicine – Kokilaben Dhirubhai Ambani Hospital

12:45 pm – 12:55 pm – Key note session on “Data Science & future of Healthcare” Ms. Zoya Brar – Founder and CEO – Core Diagnostics

12:55 pm – 1:10 pm – Company presentation on “Instruments Reprocessing” by Gaurav Arya (RSM) – Johnsons and Johnsons

 1:10 pm – 1:30 pm – Company presentation “Know your Medical Gloves” by Sameer Shah – MREPC ,Malaysia

 1.30 pm – 2.15 pm Networking & Fellowship Lunch

2.15 pm – 3.00 pm – CEO’s Panel Discussion – On Medical Value Travels – Not just mitigating health requirements, need to address other predicaments.

Besides providing best of the medical treatment to a patient from another country, there are various other factors to be taken into account by the host country. Time has come when we address some issues, concerns and leverage synergistic actions from all stakeholders.

Moderator :
Dr. Harsha Vardhan – Founder & Group MD- MedAchievers Pvt. Ltd. & Genome Analyst
Prof. Dr. Sanjeev Bagai – Vice Chairman & Director – Manipal Hospitals – Dwarka
Col. Hemraj Parmar (Retd.) – CEO – B R Life Hospitals
Dr. Mradul Kaushik – Director – Operations and Planning – Radiant Life Care Pvt. Ltd.
Yateesh Wahaal – Executive Director – Nayati Healthcare & Research Pvt Ltd
Krish Sundaresan : MD and CEO – Patni Healthcare
Dr. Sunil Khetarpal – COO – Rajiv Gandhi Cancer Hospital

3.00 pm – 3.15 pm Networking & Fellowship tea/coffee break

3.15 pm – 4.00 pm – Panel Discussion : Affordable Access to Medical Devices

Need for an integrated and cyclical approach to managing health technology in order to mitigate clinical and financial risks and ensure acceptable value for money.

Moderator : Sanjay Jha – Co Founder – Collateral Medical Pvt Ltd.
Dr. KK Agarwal – President (Elect) Confederation of Medical Associations of Asia and Oceania
Rajiv Nath- Forum Co-ordinator AiMed
Malini Aisola – Co-Convenor – All India Drug Action Network (AIDAN)
Gurmit Chugh – MD- Translumina Therapeutics
Sumeet Aggarwal – Managing Director – Midmark (India) Pvt. Ltd.
Mala Vazirani – Executive Director – Transasia Bio-Medicals Ltd

4.00 pm – 4:45 pm- Healthcare Business Intelligence – Improving efficiency and productivity?

Healthcare service providers have started using HIS & LIS but are still not using BI tools to improve efficiency and productivity. How to address this issue?

Moderator : Dr. Saktimaya Mohapatra – Founder – Midbrain – The Intelligent Healthcare
Panelist :
Vikram Anand – CEO – Capbuild Clinical Skills
Siddharth Sangwan – CEO – Hindustan Wellness
Rohit MA – Co Founder & MD – Cloudnine Group of Hospitals
Dr. Manu Bhandari – CEO – Avantha Technologies
Anoop Mohan Arora – CEO – ITDOSE Infosystems Pvt.Ltd.
Amit Mitra-Partner-Audit and Assurance – MSKA and Associate (A BDO Global Network)
Rangarajan Iyengar – CEO – HCL Healthcare India
Vinesh Gadhia – COO – Nova IVI Fertility
Dr. Saarthak Bakshi – Founder – International Fertility Center

4:45 pm – 5:00 pm – Key note session on “Building a holistic health care system” by Dr. Sy- Ming Guu, Chairman – Mytrex Health Technologies

5:00 pm – 5:05 pm- – Vote of thanks by Mr. Gaurav Malhotra – Conference Co – Chairman

Agenda Day 2

10.00 am to 10.30 am -Lamp lighting and registration

10.30 am to 11.15 am – Inaugural session

VOH Journey – Depth and Breadth of it.

Welcome address by Distinguished Guest

Dr. (Prof) Rajesh Shah

VOH Update by Chairman, VOH

Dr. Naveen Nishchal

Address by Conference – Co Chairman – VOH

Mr. Gaurav Malhotra

Address by Guest of Honour

Dr. Anil Kohli – Padmabhushan , Padmashree and Dr. B C Roy awardee

 Dr. V G Somani – Joint Drug Controller General of India

Prof. Balram Bhargava – Director General – ICMR

Neeraj Daftaur – Officer on Special Duty – CM – Haryana

Message from Chief Guest

Dr. Indu Bhushan

Felicitation of dignitaries by Associate Director – VOH

Ms. Pinky Chahar

11.15 am – 11:45 pm – “ Interactive session with Planners – Providers – Patients of Ayushman Bharat- Let’s hear the story, Directly from the Horse’s Mouth”- Moderator: Dr. Dinesh Batra : CEO – Cygnus Hospitals


The need of the hour is ‘men on mission’. Men who can take charge and make a difference for the better. A Game Changer “ has to face both the brickbats and the applauds…all in a day’s work. You win some ,you lose some. The zeal to improve and excel is the key

Moderator : Gaurav Malhotra : MD, Medicover Healthcare
Panelist :
Dr. Indu Bhushan – CEO – Ayushman Bharat
Dr. Anil Kohli – Past President Dental Council Of India, Consultant to President of India
Col. Hemraj Parmar (Retd.) – CEO – B R Life Hospitals
Neeraj Daftaur – Officer on Special Duty – CM – Haryana
Prashant Sharma – Managing Director – Charnock Hospital
Neeraj Lal – Cluster Head & VP Bangalore Operations – Rainbow Hospitals
Prof. M Wali – Consultant Physician – Former President of India
Dr. Dinesh Batra – CEO – Cygnus Hospitals
Vivek Tiwari- CEO- Medikabazaar
Mukesh Sabharwal : COO – Apollo Spectra Hospitals

12:35 pm – 12:45 pm – Company presentation on “Towards a new era of Healthcare: Raising flexibility via mobile medical services & applications” by Yao Cheng Tsai(Andru), ASM – EBM Technologies

12.45 pm – 01.30 pm – E-pharmacies – Conundrum on legality

Evolution of the E-pharmacies in India has a flourishing presence, but an uncertain future. What should we expect from the regulatory think tanks in the near future?

Moderator : Saurabh Kochhar – Co-Founder and CEO – Meddo
Dr. Varun Gupta – VP – Medical & Regulatory – 1 Mg
Vikram Anand : CEO – Capbuild Clinical Skills
Amit Bhatnagar – Country Head – Origio
Manvinder Singh – Partner – J. Sagar Associates (JSA)
Navpreet Singh Ahluwalia – Partner – Khaitan & Khaitan
Dr Prabhu Vinayagam- Founding Director-Prozela Healthcare Pvt Ltd
Rahul Chauhan – Director Regulatory & Medical Affairs – South Asia – Reckitt Benckiser

1.30 pm – 2.10 pm Networking & Fellowship Lunch

2.10 pm – 3.00 pm – Panel Discussion – “Healthcare Accessibility- After Affordability, how to bridge the gap of accessibility?”

Rural India is devoid of basic healthcare services even after various organisations have put their best foot forward.

Affordability is being addressed by numerous programmes (Ayushman Bharat, other yojanas keeping the same thoughts).


How do we bridge the gap to increase accessibility?

Moderator : Dr. Parvez Ahmed – Ex-Group Medical Director, Rainbow Group of Hospitals Hyderabad
Panelist :
Md. Ameel – Sr. Consultant – National Health System Resource Center (MOHFW)
Mahendra Pala – VP – Business Development – Gleneagles Global Hospitals
Dr. Sachin Gupta – CEO – Salus Healthcare Resources
Dr. RM Chhabra – Founder President – North Delhi Physician Forum
Zakir Hussain – CEO- Al-med Equipment

03.00 pm – 03.10 pm- Networking & Fellowship tea/coffee break

03.10 pm – 05.10 pm- Startup Spotlight- Pitching session for Healthcare Startups

Perzue Health Pvt Ltd
Arogyam Medisoft Solution Pvt. Ltd
Kairos Solution – Excelling in the Business of Healthcare
Navia Lifecare
Incredible Devices
Gravitas Consultants Limited
followed by Panel discussion – Investment Scenario in Indian Healthcare Industry- “Tech Vs. Conventional Model”

Indian healthcare tech start-ups and platforms are enthralling a lot of investors attention. How would we define the future of the conventional Healthcare models?

Moderator : Gaurav Malhotra :MD – Medicover Healthcare
Panelist :
Dr. Raajiv Singhal – MD – Head of Healthcare Operations India – The Evercare Group (UAE)
Mohit Khullar – Director – Healthcare – O3 Capital
Denny Kurien – CEO & Founder – Keiretsu Forum
Dr. Preet Pal – Co Founder – Alkemi Venture Partners
Dr. Vishal Bansal – CEO – Healthstart
Dr. Rahul Garg- Reinsurance Corporation of America, Inc, Toronto Canada
Dheeraj Rathi – MD – Ecovis RKCA Ltd.(Global consulting firm)

05.00 – 05.10 pm – Honours and Distinctions for best startup initiative by Gaurav Malhotra – Conference Co- Chairman

05.10 pm – 05.25 pm : Company Presentation on “Neonatal oxygen therapy” by Wei Hanpeng – S S Technomed Pvt Ltd.

05.25 pm – 05.30 pm – Vote of thanks by Gaurav Malhotra – Conference Co Chairman

05.30 pm- Wrapping up by MC

About the Conference

This conference is taking place against all the backdrop of disruptions and constraints of healthcare delivery system. The only way to move forward especially in healthcare where huge investment is a norm, to proactively mobilize key stakeholders from both public and private sectors along with their proud strengths and innovations on such a common platform. Hence this conference assume strategic significance as speakers share their practical approach while dealing with various issues

Inaugural session

Dr. Naveen Nishchal Chairman - Voice of Healthcare Co - Founder - Meddo Co - Founder - Cygnus Hospitals

I am profusely elated with the kind of support I am receiving from all of you- especially speakers and delegates. Medical Fair India is the largest Medical Fair of India and it’s all because of Messe Dusseldorf and hard work of Thomas Schlitt and his team. My absolute admiration for Thomas and his team. Medical Fair is not a platform only for exhibition, exhibitors, visitors, it is a platform where we interact, innovate, discuss different ideas , share knowledge and much more. Voice of Healthcare and MFI bonding is old and strong and I am thankful to MFI team that they have deep belief in us in big way. We have been doing conferences in Mumbai and Delhi on alternate years and I am sure we will keep doing all these conferences in coming years as well. This time in the conference we have our International Partners National Cheng Kung University Hospital from Taiwan- I am thankful for the team from Taiwan. I am also thankful for our conference co-chairman Gaurav Malhotra, our General secretary Afzal Kamal, Messe Dusseldorf team of Thomas and Surojit Bit and Thankful to our Guest of Honour Dr Atul Nasa. I wish the programme a big success. Next three days you will get an opportunity to interact with like-minded people, discuss things one-to-one, exchange ideas and innovate.


A very good morning to the organizers and distinguished delegates! I deem it a great honor and privilege to be here this morning at this inaugural ceremony. Of course it is accidental in the sense that the organizers had invited Honourable Shri Ashwini Kumar Choubey Ji, the Minister of State for Health and Family Welfare but due to unforeseen circumstances he could not come.

So the Honorable minister sends his sincerest apologies for being not here and conveys his greetings and best wishes to the organizers and to all the delegates. I just wish to say a few words about the National Health Policy 2017. The NHP 2017 aims to make healthcare in India affordable, accessible and qualitative. It also takes into its ambit Allopathy, Ayurveda, Yoga, Unani, Siddha, Homeopathy and Naturopathy to make the healthcare basket wider and make it easier for people to choose from which system of medicine they consider helpful.

As you all know that the Ayushman Bharat was launched by the Honorable Prime Minister on 23rd September, last year. It aims to revamp and upgrade our Primary Healthcare Centers into 1,50,000 health and wellness centers across the country. They will be upgraded and duly equipped with all the medical devices, diagnostic facilities, doctors and healthcare practitioners by the end of 2022.And the Ayushman Bharat brings into its ambit about 10 crore families which means almost 50 crore people will be covered. And they will have a health cover of Rs. 5 Lakh per annum per family. The government is committed to give healthcare to our people, to make it accessible, affordable to all the people, particularly the weaker section and the vulnerable sections.

I am sure that the discussions you will hold here in the next 2-3 days will be immensely beneficial, mutually enriching, positive, tangible recommendations will emerge from this conference and certainly they will be submitted to the government for their consideration.


Good Morning ladies and gentlemen, dignitaries on the dias and off the dias and our international partners from Taiwan. As I announce the formal inauguration of the Voice of Healthcare Conference, I would like to request our Conference Co-chairman Mr. Gaurav Malhotra to please join the dignitaries on the stage. On behalf of Voice of Healthcare, I welcome you all to the 25th Edition of Medical Fair India and 4th International Conference of Voice of Healthcare. We are very excited to host this very important conference and really feel proud and honoured to be organizing partner of Medical Fair India and Messe Dusseldorf. May I please request Mr. Surajit Bit, Director, Projects, Messe Dusseldorf India Pvt. Ltd. to please deliver a vote of Thanks.


Good Morning ladies and gentlemen, boys and girls I consider it as a great privilege to propose a Vote of Thanks to all the dignitaries who have gathered here to begin and witness the 25th Edition of Medical Fair India. On behalf of Messe Dusseldorf India, I would like to express our gratitude and want to thank our Chief Guest Shri Devender Singh Ji on behalf of Shri Ashwini Kumar Choubey Ji who has graced this occasion with his thought provoking address to set a perfect tune for the fair. A hearty thanks goes out to all our exhibitors, sponsors, partners, all our stakeholders and colleagues of Messe Dusseldorf Group who always stand by us, guide us, lead us and motivate us to make this edition a big success. Special thanks to Mr. Rajiv Nath Ji for having a belief that E-Med is right platform to have at Medical Fair India. I would like to thank Ms. Veena Kohli to graciously agree to chair the CLIN LAB CONFERENCE. I would also like to thank the Voice of Healthcare team led by Mr. Afzal Kamal and Dr. Naveen Nischa


Good Morning, members of Voice of Healthcare, delegates from Taiwan, other professionals from the field of pharmaceuticals, medical devices and other related industries. My special congratulations to Voice of Healthcare for hosting this event. I would like to share one of the important notifications that Government of India has made mandatory while giving any permission for any product formulation that B.A. or B.E. studies are not compulsory and even stability studies of all the drugs. Once you are applying to Drug Control Department for getting the approval, you have to submit stability study data reason being, quality. And in the Drugs and Cosmetics Rules, 1945, it is well defined under rule 71,76 that stability study data are to be submitted while taking the approval. But most of the small scale pharma companies were not doing so. So now it is mandatory for each and every category company to submit stability study data.

Now I would like to discuss the issue of generic versus branded, it is the dream of Honourable Prime Minister that medicines should be sold particularly by generic names. Advisory has been issued by the Medical Council of India that let us all the doctors, all the medical practitioners must prescribe the medicine by the generic name. But in the eyes of the consumer, generic medicines are not effective which is not true. Pharmacologically if you see, any medicine whether it is generic medicine, branded generic or branded, they are equally effective for all types of diseases, all types of body ailments and we have to change that perception. The government has started Jan-Aushadhi-Kendras all over the country with a target of 5000 retail outlets all over the country to make available to the costumers all the generic medicines at affordable prices. But there is an issue of quality. That’s why as I told B.A. / B.E. studies are mandatory for granting any approval for product formulation to any manufacturer. This is how the system works.

 So out of your two days conference if you think something is to be done by The Government of India, by discussing that amendment or suggestion or advice whatever you feel better whatever you feel better, forward to our e-mail id we will take that issue with the DCC. Thank you very much.


Good Morning everyone! I would like to express my appreciation to the organizing committee, specially Dr. Naveen to invite us to participate in this big event. The NCKU provides a platform for the university researchers and people from the industry to improve the quality of healthcare. 25 years ago, the Government of Taiwan launched the national health insurance program. Before that it was difficult for the poor people to get health insurance. Since 1994, all the people were covered by Universal Health Program. So over the last two decades of efforts the health condition of the people of Taiwan improved quite a lot under the Policy of Taiwanese Government. There is a new policy called the South-Span Policy. So we would like to have more and more co-operation with the countries in the South-Asia and South-East Asia. We always can learn from each other to improve the healthcare of our people. So I and my colleagues were very happy to participate in this wonderful international conference and we hope that we can learn from you and we can share our experience with you. So lastly I would like to express my best wishes for the success of this international conference. Thank You very much.


Good Morning ladies and gentlemen, I am Dr. Hsu l Lin. I am a chest surgeon and trauma surgeon. I have come to India more than ten times since 2008 mostly to the rural areas for public health for the promotion and education. This time I have come here to represent the Government, Ministry of Health to promote partnership between India and Taiwan and today I will share with you about Taiwan Healthcare. In Taiwan our population is 23 million and our life expectancy in 80 which is the same as in the OECD countries. Our infant mortality rates is 4. The top 10 causes of mortality are cancer, heart diseases, pneumonia, stroke, diabetes, etc. If we talk about cancer, there is lung cancer, liver cancer, oral cancer, breast cancer, cervical cancer which can decrease because since 2010 we have free cancer screening. And we also have latest techniques and a comprehensive transplantation programme in Taiwan and the best survival rate of heart, liver and other organ transplantations. In our future plans, we will build up psychology health center and woman and children center. We have only 2% of hospitals in Taiwan. Most of the doctors in Taiwan serve in the clinics. But for the 2% hospitals we need accreditation by JCT. We have only 19 Medical Centers and 83 regional centers and 400 district hospitals. In Taiwan the available beds for the medium hospitals is 162 per thousand population which is same as the beds with OECD countries. The expenditure for healthcare is 6% of the GDP. We have unique single pay National Health Insurance. We cover 99.6% of Taiwanese population and 93% hospitals and clinics have contracts with the Government of Taiwan. Our health insurance covers everything in-patient, outpatient, dental, even a traditional Chinese Medicine Therapy. And because National Health Insurance is controlled by the Government of Taiwan, we can provide the best quality. I know that the number is much lesser than it is in India. But besides the medical service, we also have the new growing medical industry. The growth in contact lens is almost the half of the medical industry. We also have medical service, device and equipments and medical chemistries. We have very good dentist grafts and other medical equipments. Our exports and imports are in the US, Japan and China. I think in future India will be our main partner. With this I end my speech. Thank you very much.

SUMIT MARWAH C.E.O, Dispoline Pvt Ltd

 The difference between a mask without a filter and a mask with a filter may be 10 or 15 Paisa. So if an average size hospital is using 500 masks a day, between 50 and 70 Rupees is the cost everyday. That’s all. And it’s not about a mask. I am just using it as an example. Today the cost has come down. It happened with syringes in India. It didn’t happen in one day. It took years. And today the cost is very different. But how do we buy syringes in India? We don’t buy them only on cost and quality, we buy it on the basis of cost-MRP gap? Can I buy it for Rs.5 and sell it for Rs. 50 to the patient? That’s how we buy. Truth can’t change. What I am trying to show you is unusual suspects. I don’t know if you can see the photograph, it’s of a doctor whose gown that he is wearing gets washed once in a while. The food that goes into the hospital today. I love all healthcare professionals who go to the hospitals, speak on the cell phone, do everything and then go back home and just get their hand cleaned. Any idea how much they infection they carry in their cell phone back home? No. Never mind. So we are talking about the safety of the patient and the staff. Just a quick run through Indian Medical Device Rules came out in 2018. Just one thing. I wouldn’t dwell on that much. But there is something else that has existed so far. Something called Pinaki and ISO 13485 or IC meds which is India-specific. Do we ensure that hospitals buy products from factories that comply to this? Not from anywhere.

Day 1


Topic – Healthcare Quality- Where We Are Heading To
R. NEERAJ JAIN, Secretary, Association Of Practicing Pathologists
DR. BARNALI DAS, Consultant, Laboratory Medicines, KD Ambani Hospital And Chairperson, American
Association Of Clinical Chemistry Indian Section.
MR.BADRI IYENGER, Cluster M.D., SAARC &ASEAN, Smith And Nephew Healthcare

Dr B.K. RANA : What do you think as a provider of lab diagnostics only one thing you should do to make sure that patients receive the right results?

BARNALI DAS : There are two aspects of the lab-life- one is the cost and the other one is quality. We need to basically harmonize between these two aspects.

B.K. RANA : If you get the patients to test, results are not good, then again results are not good, then again results are not good so patient will be dying in suffering. We cannot afford to be providing wrong results. Not deliberately of course. ABC reasons. So patients should get correct results. So before this reaches to the patients, we make sure things are up.

BARNALI DAS : Yeah. Because of that quality comes. Affordability and costs everything comes so that the patient can have a smooth ride in that bicycle.

MODERATOR : So Rajiv, I will come to you. What your industry is doing to make sure patient is safe?

RAJIV : To ensure patient safety, a company will have to follow quality management standard. Also, they follow risk management. These are the two basics I would expect the company to do in medical devices.

B.K. RANA : See Rajiv the situation is that people are not aware of QMS and Risk Management System. So first thing is basically to educate everyone. Then only we can talk about that. What is being done for that?

RAJIV : That’s why we have these forums and these discussions. So that people can understand because what anyone talks about is in terms of performance quality. Manufacturers think about producing better products than their competitors. Apart from following not only the quality management system standards or the Topic- Healthcare Quality- Where We Are Heading To

B.K. RANA : So linking you to Quality Management System we have a representative of an accreditation body who is accrediting certification bodies for different Quality Management Systems, so Shashi my question to you is what should be the role of accreditation body to ensure what Rajiv was mentioning good QMS and Risk Management is in place for the entity that the accreditation body accredits.

SHASHI REKHA : I think I am very clear about what our role is. I would like to say we’re doing that. When we are accrediting as per MDR 2017. So what our role is that first of all, accreditation itself means that do these conformity assessment bodies or notified bodies have the competence to audit for ISO:13485 and meaning of accreditation is demonstration of competence. So to ensure that the notifying body has competence we ourselves must have competence. It’s only possible then that we can assess competence. So NABCB will ensure that it uses technical experts who have the competence for various kinds of medical devices We make sure that the notifying bodies have the competence to assess those medical device manufacturers. That is what is required.

B.K. RANA : Sanjeev you have been in defence services in healthcare area and part of the accreditation bodies. So as an evaluator or as an assessor or as a surveyor of accreditation body what primarily you would see the compliance with competence criteria?

SANJEEV SOOD : So if you look into the technical competence one thing is that we have to look into the accreditation of the healthcare providers who are delivering the healthcare. The Second thing is that we have to go into the technical area like the standard treatment guidelines or the protocols or SOPs are in place or not.

B.K. RANA : Do we have the Standard Treatment Guidelines here in India?SANJEEV SOOD : Yes. The Standard Treatment Guidelines have now been stipulated by various organizational bodies. We have antibiotic policies and stewardship programs.

B.K. RANA : Okay. Good. But we don’t have STG in lab medicine norms. So Neeraj you have been in different roles including capacity building. So the laboratory professionals provide good knowledge. What has been your experience at the end when you delivered the things how it makes an impact in the healthcare delivery?

NEERAJ JAIN : When we teach people about quality it definitely makes an impact but the only thing is the time gap between our delivery and their implementation. Sometimes people confuse quality with the accreditation. They think we need quality implementation only when they are going for accreditation. If they are not going for going for accreditation then they think that quality is not required but if they find it is of immediate use for them, then they go for quality accreditation.

B.K. RANA : So thank you very much ladies and gentlemen. Thank you for your time. Thank you for being here and for your patient listening. Conclusion from the Panel DiscussionQuality aspect in Healthcare is not Just limited to Accreditations. Although it’s a major challenge in Indian Healthcare Scenario, but can’t be overlooked. Not just the service providers, but a collective effort from all stakeholders like Pharma, Medical Devices, Diagnostic services, Technology, Informatics, health education system- everyone has to participate and pitch in effectively to achieve a comprehensive heathcare quality model. Importance of Public awareness for various quality accreditation was also emphasized upon.


Topic- On medical Value travels- Not just mitigating health requirements, need to address other predicaments
COL. HEMRAJ PARMAR, Group CEO, BR Life Hospitals
DR. HARSHAVARDHAN, Founder And Group MD, Medacheivers Pvt Ltd. And Genome Analyst
PROF. DR. SANJEEV BAGAI, Vice Chairman & Director, Manipal Hospitals, Dwarka, Delhi
YATEESH WAHAAL, Executive Director, Nayati Healthcare & Research Pvt. Ltd.
DR. SUNEEL KHETARPAL, COO, Rajiv Gandhi Cancer Hospital
MR. GAURAV MALHOTRA : MD Medicover Healthcare & Conference CO-Chairman, 

COL. HEMRAJ PARMAR : Good afternoon ladies and gentlemen. Thank you so much panelists and hearty welcome to the stage. We have world-renowned doctors who are trained in some of the best healthcare countries such as in The US, North America, in some of the European countries and they bring global clinical excellence. Some of the best hospitals in India are also comparable with some of the best hospitals in the advanced countries where people get the best treatment outcomes. We in India can do the same at a fraction of the cost. So moving on, as you all know, that opportunity is immense in India. How do we leverage it? What is the infrastructure which is required? What are the policy parameters that we need to look into or we expect from the Government agencies to help us with? How can they contribute to the medical value travel? How will it impact the medical value travel industry are some of the issues that we would like to discuss in this forum. I think we will have a very educating session. So just to set the ball rolling my first question is to Dr. Harshvardhan as to what is the opportunity that we see for India as a preferred destination for medical value tourism? What needs to be done and how do you think we can make it sustainable?

HARSHVARDHAN : We know that India is the most preferred destination for patients from the developing countries. They are looking towards our healthcare systems, they are looking towards our doctors in a different way. They want us to come, deliberate and showcase something that they don’t know about us. So I think more of deliberations are needed first to bring advanced countries closer to India. Also our medical tourism industry is still in the facilitator zone more than the doctor zone. We have to somehow open up ourselves and interact more directly with the patients than the doctors’ community across the border just to ensure that we are more visible. So these are two things that I have in my mind.

 COL. HEMRAJ PARMAR : Mr. Malhotra.

GAURAV MALHOTRA : From my experience in our multi-specialty or singlespecialty chain of hospitals, I can surely say that almost 15-20% of our business is coming from international patients. In my opinion there can be certain policy interventions from the government and there can be more incentives.

 COL. HEMRAJ PARMAR : So one issue which you touched upon is the policy. There are a lot of regulatory issues which have to be taken into account. The onus is bigger on the healthcare providers that they do not fall prey to the greed garner more revenue from them. So over to you Mr. Yateesh.

YATEESH WAHAL : One needs to break this certain issue into many parts. What needs to be analyzed is that talking about the MVT Industry as a USD 50 million Industry. In India it is 10% of the medical Industry. Compared to the developed countries we are affordable but not cheap. On the other hand just like the tourism has got moved in, you have got war-zoned countries from where a lot of people will come. The medical visa, say about a decade or two decades back was relatively easier because the business visa would be difficult. Now with e-visas being introduced it’s easier to come as a tourist. There has to be some working that has to go and to try and get the e-medical visa fast-tracked. It has to be a multi-entry. So those are act-upon points which will eventually result in unfolding a larger picture.

COL.HEMRAJ PARMAR : Very good point. I think now the government has come up with the provision that the patient coming with a business-visa or a tourist visa can also undergo treatment in India.

YATEESH WAHAL : That’s only for emergency. Now that’s what again I am saying. Why two times? Why not evolve the process together?

COL. HEMRAJ PARMAR : This is a takeoff point for policy makers that we need to have policies which ensure that the patient’s and the providers’ interest are kept in mind. Also there must be a bundling of the tourist packages along with the medical packages. With 4 lakh visitors we are generating a revenue of about USD 3-4 billion. Imagine the amount of revenue we can generate. So full points there and over to you Sanjeev.

SANJEEV KHETARPAL : I think that in the MVT, facilitator is an important stakeholder. And the NABH has come out with standards for health value travel facilitators. There are 13 facilitators which have NABH accreditation. There are not many. So you have to choose your facilitator very wisely. It is not that any Tom, Dick and Harry can come in this market and do business. And there are a lot of dirty things happening in this market. We need to control that. We have to be fair, ethical and ultimately we have to think about the patients.

COL. HEMRAJ PARMAR : So you are saying is that the market is currently very fragmented. We need to organize it. And the government will come to a policy framework subsequently in order to promote medical tourism and also create the requisite infrastructure to build that exellence. Thank you so much and over to you Dr. Sanjeev.

BAGAI : I would like to add a point to this. Whenever you are dealing with a facilitator, there should be a registry of healthcare facilitators pan India. Like we have FRO in which the patient’s screening is done, pass-port is checked, date of entry and date of exit is checked, tickets are checked, foreign exchange is checked. I think the facilitators must have a registry. That’s the reason I am saying it is completely unorganized segment at present.

COL. HEMRAJ PARMAR : Krish. MR. KRISH SUNDARESAN: Dr. Bagai had touched upon some very important points. When we use the term medical value tourism we are actually destroying the product. So we have to move away from that in the long run. Today we are capturing only those who are coming in because they are catered to by some facilitators or agents. We need to move from this stage to build a brand for Indian healthcare delivery by proactively going to those countries and doing value added programs. Let’s build direct connection with patients through digital medium or through the other things that we are doing. And this is the way we have to look at it. COL. HEMRAJ PARMAR With this I would like to conclude the panel discussion. Conclusion- Besides proving best of the medical Treatment to an International Patient, a host country , like India should consider many other points to improve upon global acceptance of MVT in India. All stake holders should work in symphony towards a single goal and maximum leverage has to be milked when situation is favour of India. Govt need to put a well drafted policy in place, the felicitators have to be regulated, visa approval/processing/other formalities should be seemless and quick, rather than the hospital infrastructure and facility, doctors should be the front face and a direct communication with patients cross the globe through digital media were the points which were emphasized upon.


Topic- Affordable Access to Medical devices
MODERATOR : SANJAY JHA, Co-Founder, Collateral Medical Pvt. Ltd.
DR. KK AGGARWAL, President (Elect) Confederation of Medical Associations of Asia and Oceania
RAJIV NATH, Forum Co-Ordinator, AIMED
MALINI AISOLA, Co-Convener, All India Drug Action Network (AIDAN)
GURMIT CHUGH, MD, Translumina Therapeutics
SUMEET AGGARWAL, Managing Director, Midmark (India) Pvt. Ltd.
MALA VAZIRANI, Executive Director, Transasia Bio-Medicals Ltd.

K.K. AGGARWAL: Somewhere all of us including the doctors are not able to understand the meaning of NLEM i.e. the National List of Essential Medicines. Devices also are a part of the NLEM as per the act and as per the definition of NLEM. But for all the medical devices, one device should be NLEM and one should be non-NLEM. Give the choice to people. The Government did a mistake of putting all the stents into NLEM. They have to give evaluation. For example, Sirolimus and Everolimus. So Sirolimus, Everolimus, Zotarolimus, they say are same. Then you take one of them into NLEM and other into non-NLEM. And if that is not going to come back the industry is going to have problem. Somewhere there is a mistake and there is a confusion. So people think non-NLEM is better than NLEM which is not correct. Both are different.

SANJAY JHA : So moving on to medical devices. One of the ways to make medical devices affordable is price-capping by the government. We have seen that in Pharma Industry, in the cardiac stents. I would like to ask Mr. Rajiv Nath how does price cap on medical devices help Make-In-India? MR.

RAJIV NATH : Let us go back to history. A few years back the Indian medical devices were keeping their MRP on the unit label. The imports were not keeping unit labels on their devices. They were keeping their devices in the shelfbox. Consumers like you and me do not buy medical devices in a shelf box but individually. And the chemist in the hospital had a plan-check to charge whatever price through which he could get more profit. So we sought the government to intervene unlike pharma. We do believe that there is going to be regulation and also ethical marketing. It will help domestic manufacturers. That’s why we are seeking price control. Not necessarily price-caps but also the trade margin could be possibly capped over the import landed price or the expected price to a reasonable level. Thank you.

SANJAY JHA : Malini besides your work on regulations controlling the prices of drugs and devices, you are also involved in campaign for dignified and affordable healthcare. There are recently notified DTCO amendments in relation to medical devices . Would you highlight and talk about that.

MALINI AISOLA : Before that I would like to say that AIDAN broadly agrees with everything that Mr. Rajiv has said. There is just one point of departure which is that we are much more interested in seeing price caps on medical devices instead of trade margin rationalization which is the other proposal. For the most commonly used ones or the critical ones there needs to be a price cap. I think that the trade margin rationalization by itself is not going to remove any of the market distortions. We are still going to see a very wide range of prices and we are not going to see price reductions in the MRP that would be required to make those devices affordable. So these are just my comments.

SANJAY JHA : Mala, Transasia has come a long way in the last 14 years and it has been a very passionate advocate of Make in India initiative. How is Make in India working right now? Is it helping affordability? What have you seen so far and how do you see it going forward?

MALA VAZIRANI : Make in India makes sure that overseas companies come to India and acquire Indian companies for global markets. So let anybody out there wondering about the quality of so and so forth know that there is a lot to be gained from Make in India. As far as Transasia is concerned we have been filling a huge gap in the country for affordable diagnostics that is laboratory blood testing. It is actually the backbone of the entire medical care system. Hospitals cater to a large number of patients. And there would be a domino effect on the entire hospital and for the patients if the lab wasn’t to function and the equipment in the lab wasn’t to function. So if we are having great outcomes in many of our hospitals, it is because of the medical equipments made in India that are supporting their work.

SANJAY JHA : Thanks! And that takes us to Mr. Gurmeet Singh. You have been able to keep your products affordable. How you have been able to do that?

GURMEET CHUGH : Usually people are of the opinion that only a multinational can produce good quality. But we have proven them wrong. I think around four months back Translumina became the first company in the world to establish the clinical evidence of a drug eluding stents for ten years. And this was accepted as the largest clinical evidence as a drug eluding stent in the world. Now we have been called upon by one of the most credible bodies of the world in terms of the healthcare practices or cardiology practices which is American Heart Association. It is possible for any healthcare company to achieve what we have achieved. The perception that it is impossible for an Indian company to reach up to such a high level of excellence needs to be changed. So I think affordable access to healthcare is very much possible if the government decides to first change this perception. If this perception doesn’t change, there is no future.

SANJAY JHA : Mr. Sumeet what do you think would it be a very big competitive disadvantage for Indian manufacturers who are seeking a level playing field with the overseas manufacturers?

MR.SUMEET AGGARWAL : I think that the key thing is that as an American company we believed in the Indian capability. Now we have taken it forward. I just want to ask if the government really understand the capabilities of India. Many times what I see is that despite us investing in a manufacturing company under Make in India, the government incentivizes others who are not manufacturing in India, selling their products in India, importing their products in India and the duties are so low that they are able to come and make Make In India actually unsuccessful. So for US Dollars that are earned through medical tourism the government provides an EPCG brand to them to further get capital goods at a price point where the Indian manufacturer may become noncompetitive. And I think that has to change very quickly. I think the government really needs to understand where the capability of India today is whether it is about manufacturing of high end medical devices but the duties have to be put in place.

SANJAY JHA : Mansi! You are from investment banking business. How do you see the investments that are happening in the areas which are making affordability accessible to the consumers? MS.

MANSI AGGARWAL : So I just have a slightly contradictory point of view to this panel because I come from the investment background. I understand that affordability and profitability have to go hand in hand as far as investors are concerned. Mr. Rajiv made an important point that we shouldn’t profit here but we should still have enough margin for the businesses to become viable. The greatest issue is the regulatory risk of price control that actually hampered any investment in this sector. I think the investors’ sentiment is that medical industry is where pharma was about 20 years ago. Today the market cap is about USD 300 million and it is expected to be 30 billion by 2030 which will attract a lot of investment. The high end medical technology startups will take away the point of care maybe from the hospital to homes. So that’s where a lot of investment will come and the healthcare accessibility for patient will increase over time and that will lead to better prices, better affordability in future.

SANJAY JHA: With this I conclude this panel discussion. Conclusion- Affordability of medical Devices is an important aspect of overall affordability of healthcare. The role of price capping to keep prices of medical devices under control was discussed. It was suggested to cap trade margin rather than Capping MRP for ethical and reasonable sustainability. “Make it India” was considered as another solution to affordability by one of the panelists, with a catchpoint to the Govt not to take the import duty so less for the importors of Medical Devices so that finally Making in India becomes costlier compared to import. It was emphasized to change the perception of Govt in particular and people of India at large that indigenous medical devices are , quality wise, at par (if not better ) with imported counterparts. Because at the end of the day, even if we achieve the target and make all medical devices affordable, but the devices are not acceptable to the Government/End users, doubting its efficiency and quality , then the whole effort goes down the drain. If this perception doesn’t change, there is no future.

Day 2 - Inaugural session

Dr. Indu Bhushan CEO, Ayushman Bharat - (AB - PMJAY) National Health Agency (NHA)

Good  Morning everyone! Over 12 lakh people have received free treatment under the Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana, while around two crore beneficiary e-cards have been issued since its launch in September last year,

 At least 15,000 hospitals have so far been empanelled under the scheme out of which, 15 per cent are private hospitals.

For the first time in the history of independent India, health sector has become a political commitment. The government of India has shown its commitment towards strengthening the healthcare eco-system in the country by increasing the investments to 2.5 per cent.

 The Ayushman Bharat has received tremendous response in the initial phases. We have completed 150 days and have issued two crore cards. We will be completing five months tomorrow.

Dr V G somani, Joint Drug Controller General of India

Defining  Viable Healthcare for All is incomplete without mention of viable drugs availability to every citizen of India, and before that to ensure supply to every nook and corner of India. The Drug supply to every part of a vast country like India is nearly impossible for Government alone without active participation from Private players- the stockists-distributors-retailers, who ensure the drugs reaches where it is required and destined to. They do their work efficiently and keep a small portion of the margin of profit and there is nothing wrong in it. The government cannot overlook their importance while making any policy decision while addressing Viability, Accessibility, Availability and Quality. The price capping on life-saving drugs, cancer drugs and other costly implants and stents is necessary, but the supply chain should not be disturbed.

Shri D C Jain, Chairman & Managing Director, Akum Drugs and Pharmaceuticals Pvt Ltd

Mr DC Jain Chairman & Managing Director Akum Drugs and Pharmaceuticals Pvt Ltd- a pharma manufacturing company which contributes 12% of total market share of all drugs that is being manufactured in India, also laid emphasis on the importance of stockiest-distributor- retailer flow chain and compared them as the arteries and vein of the Drug Delivery system in India. He ensured government that his company is already participating in all possible ways to ensure viability and availability without effecting Quality of drugs being manufactured in his plants.

About Day 2

22 Feb 2019, Day-2 of V OH 4th International Conference started with Traditional Lamp Lighting and Sacred Hymns of Vaidic Sloka. Distinguished Guest Dr. (Prof) Rajesh Shah delivered the welcome speech. He thanked the dignitaries for supporting V OH conference by making themselves physically available in such a large number. He emphasized upon the role of various stakeholders , in their respective field, to come together and aim at single goal called VIABI LIT Y OF H E A LTHCARE FOR ALL. A brief on V OH Update was given by Chairman, V OH Dr. Naveen Nishchal. He summarized the vision, mission and V OH journey so far. He described the way V OH has successfully attempted to weave a network of think tanks from various Healthcare Service providers along all verticals, acting as a go between for exchange of idiologies, policy framework, principles and course of action to share the needful with Govt agencies, investors and policy makers. Conference Co-Chairman, Gaurav Malhotra addressed the gathering and briefed what to expect for the proceedings of the day 2. He was excited to present the two major star attractions- Ayushman Bharat panel Discussion and Healthcare Startup Spotlight session. He urged the delegates to make their presence felt by actively participating in Q & A sessions with dignitaries on dais. Defining viable Healthcare for All is incomplete without mention of Viable drugs availability and supply to every nook and corner of India. Noted philanthropist and Chairman & Managing Director of Akum Drugs and Pharmaceuticals Pvt Ltd Mr DC Jain, along with Joint Drug Controller General of India Dr. V G Somani emphasized upon the importance of Viable Drug Delivery System India through various government initiatives. Mr DC Jain, whose company Akum Pharma contributes 12% of total market share of all drugs that is being manufactured in India, laid emphasis on the importance of stockiest-distributorretailer flow chain and compared them as the arteries and vein of the Drug Delivery system in India. Over the 2 days of the conference, the only topic which kept surfacing again and again was the most trending subject of last 6 months, i.e. AYUSH MAN BHARAT scheme of Govt Of India. Who else, other than the CEO Ayushman Bharat himself, could explain it better? Our Chief Guest for the day Dr. Indu Bhushan managed to squeeze out an hour from his busy schedule and attended the conference and explained the achievement and Journey of Ayushman Bharat- the most ambitious Project of Prime Minister Shri Narendra Modiji. The aura of his presence was nothing less than a blessing in itself. He informed that technology has become the backbone for Ayushman Bharat by making the entire system cashless and paperless. With over 50 crore population coming under the purview of healthcare, technology is going to become an even bigger market in healthcare. However, Dr. Bhushan also cautioned that technology would cost money and therefore, both healthcare providers and other stakeholders should be prepared to balance this high cost as financial allocation would be needed. “Over 12 lakh people have received free treatment under the Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana, while around two crore beneficiary e-cards have been issued since its launch in September last year”, Dr Indu Bhushan, the CEO of Ayushman Bharat said, “At least 15,000 hospitals have so far been empanelled under the scheme out of which, 15 per cent are private hospitals”. He urged more healthcare establishments to join the movement. To quote his exact words-“For the first time in the history of independent India, health sector has become a political commitment. The government of India has shown its commitment towards strengthening the healthcare ecosystem in the country by increasing the investments to 2.5 per cent,” he said. “The Ayushman Bharat has received tremendous response in the initial phases. We have completed 150 days and have issued two crore cards. We will be completing five months tomorrow,” he said. When the CEO, COO and top management of majority of leading Private hospitals of India are still scratching their heads to carve out a formula for viable adoption and practice of Ayushman Bharat scheme in their hospitals, there is one man- a visionary and bona fide craftsman of Healthcare industry- Dr Dinesh Batra, CEO Cygnus Hospitals , who has not only adopted the scheme in all 8 cygnus hospitals but also eagerly willing to share the secret formula behind successful implementation . As a moderator of an “Interactive session with Planners – Providers – Patients of Ayushman Bharat”, Dr Dinesh Batra narrated an emotional yet mathematically well calculated solution to an enigma called Ayushman Bharat Scheme.


Topic- Pradhan Mantri Jan Arogya Yojna – 4 Months
Journey For Ayushman Bharat Scheme – How Smooth Is The Ride So Far?
Gaurav Malhotra : MD, Medicover Healthcare
Dr. Arun Gupta: Executive Director Hospital Network and Quality assurance- NHA
Dr. Anil Kohli – Padmabhushan , Padmashree and Dr. B C Roy awardee
Col.(Retd.) Hemraj Parmar – CEO – B R Life Hospitals
Prashant Sharma – Managing Director – Charnock Hospital
Mr. Neeraj Lal: Cluster Head & VP Bangalore Operations – Rainbow Hospitals
Prof. M Wali – Consultant Physician – Former President of India
Dr. Dinesh Batra : CEO – Cygnus Hospitals
Dr. Sunil Kheterpal – COO, Rajiv Gandhi Cancer Hospital

The panel discussion started with a brief on journey of Ayushman Bharat By Dr Arun Gupta. He started from where his senior Dr Indu Bhushan left, “The Ayushman Bharat has received tremendous response in the initial phases. We have completed 150 days and have issued two crore cards. We will be completing five months tomorrow,”. He 15,000 hospitals have joined the movement of which, 15 per cent are private hospitals. “The future of this movement lies in a good integration between the private and public health care entities. I urge all entities to join in and make the change happen”. The panel discussed the achievements of Ayushman Bharat as more than 1.7 crore beneficiary e-cards have been generated facilitating access to quality healthcare under the scheme to 12 lakh poor across the country. Currently 14,856 hospitals have been empaneled under PM-JAY. Out of these, around 7244 or 49 per cent are private hospitals. With its focus on providing best-in-class in-patient care to the poorest 40 per cent in the country, through PM-JAY, two-thirds of the total hospital admission amount of more than Rs. 1,600 crores has been utilized towards tertiary care procedures or treatment for serious illnesses. Cardiology and cardio-thoracic and vascular procedures such as CAG (Coronary Angiography), PTCA – double and single stent (medicated, inclusive of diagnostic angiogram), Coronary Ballon Angioplasty and Orthopedics procedure such as External fixation – Long bone are the top five packages of PM-JAY worth more than Rs. 592 crores and account for 37 per cent of the total admission amount.


E-pharmacies in India has gained a flourishing foothold. The journey of evolution of e-pharmacy in really quite exciting so far, but the future is uncertain as the intricacies of legal system of India are yet to carve a win-all solution. Matter is subjudice, hence government view-point could not be accessed

Moderator –
Saurabh Kochhar – Co-Founder and CEO – Meddo and fellow
Dr. Varun Gupta – VP – Medical & Regulatory – 1 Mg
Vikram Anand : CEO – Capbuild Clinical Skills
Amit Bhatnagar – Country Head – Origio
Manvinder Singh – Partner – J. Sagar Associates (JSA)
Navpreet Singh Ahluwalia – Partner – Khaitan & Khaitan
Dr Prabhu Vinayagam – Founding Director-Prozela Healthcare Pvt Ltd
Rahul Chauhan – Director Regulatory & Medical Affairs – South Asia – Reckitt Benckiser
S L Nasa, Delhi Pharmacy Council
Dr Harish Kumar consumer activist

The panel discussed how E- pharmacy industry has become a lucrative sector in the past few years, with surge in cheap data usage and widening reach of e-commerce. It has been estimated that more than 250 online pharmacies have sprung up in India in recent years, cornering Rs1,000 crore of the Indian drug market. Leading Startup Netmeds has recently secured $35 million of funding from Daun Penh Cambodia group. Similar investments have been on rise in other online pharmaceutical companies as well such as LifCare, Pharmeasy, 1mg and others. The sector have been offering services like telemedicine at affordable prices and free delivery of prescribed medicines by connecting brick-and-mortar pharmacy stores with the consumers through mobile applications. Many organizations have been protesting against proliferation of e-pharmacies, the traditional pharmacies see them as competitors eating their pie whereas human rights groups have raised concerns over the unregulated sale of medicines leading to potential health epidemic . The panel concluded that E-pharmacy cannot be compared with normal e-commerce platform. It would be a serious concern if medicines can be bought or sold in a similar manner that of other goods on Amazon or Flipkart. They cited the example that even the sub-committee that was constituted by Drugs Technical Advisory Board (DTAB) has accepted the same and entrusted responsibilities to examine the issue of regulating the sale of drugs over internet under the Drugs and Cosmetics Rules, 1945 (D&C Rules). The sub-committee has also proposed recommendations on the matter and lately these recommendations have been published as ‘Draft-Rules’ by Ministry of Ministry of Health & Family Welfare (MOH&FW). Thus a new Part VI- ‘Sale of Drugs by E-Pharmacy’ has been proposed to be added to the D&C Rules. Though the DRA and DRC were silent on the online sale of medicines, it is imperative to examine the proposed legal structure with existing legal regime governing the pharmaceutical industry


Md. Ameel – Sr. Consultant – National Health System
Resource Center (MOHFW)
Mahendra Pala – VP – Business Development – Gleneagles
Global Hospitals
Dr. Sachin Gupta – CEO – Salus Healthcare Resources
Dr. RM Chhabra – Founder President – North Delhi
Physician Forum
Zakir Hussain – CEO- Al-med Equipment

The panel elaborated that for those who live in urban areas, healthcare may be merely a political issue as they argue that the country faces bigger challenges such as economic development, infrastructure, jobs, and border disputes with Pakistan, but for the remaining staggering 70% of the population who still lives in rural areas and has no or limited access to hospitals and clinics, it’s a matter of life and death. Consequently, the rural population mostly relies on alternative medicine and government programmes in rural health clinics. In contrast, the urban India has numerous private hospitals and clinics which provide quality healthcare. These centres have better doctors, access to preventive medicine, and quality clinics which are a result of better profitability for investors compared to the not-so-profitable rural areas. Besides the rural-urban divide, another key driver of India’s healthcare landscape is the high out-of-pocket expenditure (roughly 70%). This means that most Indian patients pay for their hospital visits and doctors’ appointments with straight up cash after care with no payment arrangements. According to the World Bank and National Commission’s report on Macroeconomics, only 5% of Indians are covered by health insurance policies. Such a low figure has resulted in a nascent health insurance market which is only available for the urban, middle and high income populations. Recently Launched Ayushman Bharat Scheme has dreams to patch this gap. The panel concluded that along with affordability, the accessibility issue can be sorted out with proper planning of Healthcare Infrastructure Development in Rural Area with introduction of more number of Hospitals and Medical Colleges in rural belts. Presently almost all of the existing Medical Colleges and Big Hospitals are urban centric. Hence the trained Doctors and Technical Staff refrain themselves from joining any rural healthcare division, even though most of them have their rural upbringing. Planning of speciality and superspeciality centres in rural area, incentivizing willing doctors those who want to shift their base to rural areas, increasing the number of medical seats in India and supporting reverse brain drain initiatives by government are some of the solutions which can be adopted to solve the issue.

Startup Spotlight- Pitching session for Healthcare Startups.


7 ambitious healthcare start ups, from across India, competed against each other while pitching their dreams to impress the Grand Jury. The participating startups were
•Perzue Health Pvt Ltd
•Arogyam Medisoft Solution Pvt. Ltd
•Kairos Solution – Excelling in the Business of Healthcare
•Navia Lifecare
•Incredible Devices
•Gravitas Consultants Limited .
 Only 6 min were allocated to each company and evaluation was done on the basis of Team Background, scalability, Idea Innovation and stage of development. Incredible Devices won the completion with thin margin point.

 Parentlane stood 1st Runner’s Up whearas Kairos Solution stood 2nd runners up.

Honours and Distinctions for best startup initiative was done by Gaurav Malhotra – Conference Co- Chairman The eminent Jury Panel of Startup Spotlight- Pitching session for Healthcare Startups comprised of

  • Dr Navin Nishchal, Chairman VOH
  • Afzal Kamal, Gen Secy VOH
  • Gaurav Malhotra, Conf Co-Chair VOH
  • Dr. Raajiv Singhal – MD – Head of Healthcare Operations India – The Evercare Group (UAE)
  • Mohit Khullar – Director – Healthcare – O3 Capital
  • Denny Kurien – CEO & Founder – Keirestsu Forum
  • Dr. Preet Pal – Co Founder – Alkemi Venture Partners
  • Dr. Vishal Bansal – CEO – Healthstart
  • Dr. Rahul Garg- Reinsurance Corporation of America, Inc, Toronto Canada
  • Dheeraj Rathi – MD – Ecovis RKCA Ltd.(Global consulting firm) Mr Gaurav Malhotra. The competing Startups gave them a real tough time.


Investment Scenario in Indian Healthcare Industry- “Tech Vs. Conventional Model

Gaurav Malhotra : MD, Medicover Healthcare
Dr. Raajiv Singhal – MD – Head of Healthcare Operations India – The Evercare
Group (UAE)
Mohit Khullar – Director – Healthcare – O3 Capital
Denny Kurien – CEO & Founder – Keirestsu Forum
Dr. Preet Pal – Co Founder – Alkemi Venture Partners
Dr. Vishal Bansal – CEO – Healthstart
Dr. Rahul Garg- Reinsurance Corporation of America, Inc, Toronto Canada
Dheeraj Rathi – MD – Ecovis RKCA Ltd. (Global consulting firm)

The panel discussed the way India’s healthcare market may see a threefold jump in value terms to reach $ 372 bn by 2022. The healthcare industry in India stood as the fourth largest employer in 2017 as the sector employed more than 3.2 Lakhs people. Key components of the healthcare market in India are hospitals (Government and Private), pharmaceuticals, diagnostics (imaging and pathology), medical equipment and supplies, medical insurance and telemedicine. Growing incidence of lifestyle diseases, rising demand for affordable healthcare delivery systems due to the increasing healthcare costs, technological advancements, the emergence of telemedicine, rapid health insurance penetration and government initiatives like e-health together with tax benefits and incentives are driving healthcare market in India. As it happened in other fields, information technology (IT) is making giant inroads into Healthcare as well. Commercialisation of Artificial Intelligence (AI) can be seen in the rapid incorporation of new applications in different areas of treatment and care. Technology is playing a significant role in making treatment less painful, time-saving and affordable. No one can deny that the Internet of Things (IoT) is the future of healthcare. Artificial intelligence and data analytics are bringing greater opportunities for the sector, offering faster, more effective treatment options that have wider affordability and acceptability. Robotics too has played a large role in improving the quality of care for patients. Robotic surgeries, radiation surgery or radio therapies with cyber knife options, and transplant support systems, among other facilities, are likely to see further advancements. The panel concluded that Technology led innovations in healthcare are bound to open doors to a newer, braver world where healthcare is much more accessible and affordable. This is particularly true for a country like India which shows a dismal ratio of 0.7 doctors, and 1.5 nurses per 1,000 patients. Here technology is playing a big role in aiding diagnosis and remote monitoring of patients through means like telemedicine, electronic ICU, etc